Carsten Denkert
On-treatment biopsies to predict response to neoadjuvant chemotherapy for breast cancer.
Sinn B, Sychra K, Untch M, Karn T, van Mackelenbergh M, Huober J, Schmitt W, Marme F, Schem C, Solbach C, Stickeler E, Tesch H, Fasching P, Schneeweiss A, Müller V, Holtschmidt J, Nekljudova V, Loibl S, Denkert C. On-treatment biopsies to predict response to neoadjuvant chemotherapy for breast cancer. Breast Cancer Res 2024; 26:138.
24.09.2024On-treatment biopsies to predict response to neoadjuvant chemotherapy for breast cancer.
24.09.2024Breast Cancer Res 2024; 26:138
Sinn Bruno Valentin, Sychra Katharina, Untch Michael, Karn Thomas, van Mackelenbergh Marion T, Huober Jens, Schmitt Wolfgang Daniel, Marme Frederik, Schem Christian, Solbach Christine, Stickeler Elmar, Tesch Hans, Fasching Peter Andreas, Schneeweiss Andreas, Müller Volkmar, Holtschmidt Johannes, Nekljudova Valentina, Loibl Sibylle, Denkert Carsten
GAIN2 trial overall survival with intense versus tailored dose dense chemotherapy in early breast cancer.
Möbus V, Lück H, Ladda E, Klare P, Engels K, Schmidt M, Schneeweiss A, Grischke E, Wachsmann G, Forstbauer H, Untch M, Marme F, Blohmer J, Jackisch C, Huober J, Stickeler E, Reinisch M, Link T, Sinn B, Janni W, Denkert C, Seiler S, Solbach C, Schmatloch S, Rey J, Loibl S. GAIN2 trial overall survival with intense versus tailored dose dense chemotherapy in early breast cancer. NPJ Breast Cancer 2024; 10:66.
30.07.2024GAIN2 trial overall survival with intense versus tailored dose dense chemotherapy in early breast cancer.
30.07.2024NPJ Breast Cancer 2024; 10:66
Möbus Volker, Lück Hans-Joachim, Ladda Ekkehart, Klare Peter, Engels Knut, Schmidt Marcus, Schneeweiss Andreas, Grischke Eva-Maria, Wachsmann Grischa, Forstbauer Helmut, Untch Michael, Marme Frederik, Blohmer Jens-Uwe, Jackisch Christian, Huober Jens, Stickeler Elmar, Reinisch Mattea, Link Theresa, Sinn Bruno Valentin, Janni Wolfgang, Denkert Carsten, Seiler Sabine, Solbach Christine, Schmatloch Sabine, Rey Julia, Loibl Sibylle
An analysis of PIK3CA hotspot mutations and response to neoadjuvant therapy in breast cancer patients from four prospective clinical trials.
Jank P, Karn T, van Mackelenbergh M, Lindner J, Treue D, Huober J, Engels K, Solbach C, Diebold K, Marme F, Müller V, Schneeweiss A, Sinn H, Fehm T, Schem C, Stickeler E, Fasching P, Budczies J, Felder B, Nekljudova V, Holtschmidt J, Untch M, Denkert C, Loibl S. An analysis of PIK3CA hotspot mutations and response to neoadjuvant therapy in breast cancer patients from four prospective clinical trials. Clin Cancer Res 2024
05.06.2024An analysis of PIK3CA hotspot mutations and response to neoadjuvant therapy in breast cancer patients from four prospective clinical trials.
05.06.2024Clin Cancer Res 2024
Jank Paul, Karn Thomas, van Mackelenbergh Marion T, Lindner Judith L, Treue Denise, Huober Jens, Engels Knut, Solbach Christine, Diebold Kurt, Marme Frederik, Müller Volkmar, Schneeweiss Andreas, Sinn Hans-Peter, Fehm Tanja N, Schem Christian, Stickeler Elmar, Fasching Peter Andreas, Budczies Jan, Felder Bärbel, Nekljudova Valentina, Holtschmidt Johannes, Untch Michael, Denkert Carsten, Loibl Sibylle
Long-term outcomes of a randomized, open-label, phase II study comparing cabazitaxel versus paclitaxel as neoadjuvant treatment in patients with triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE).
Meyer-Wilmes P, Huober J, Untch M, Blohmer J, Janni W, Denkert C, Klare P, Link T, Rhiem K, Bayer C, Reinisch M, Bjelic-Radisic V, Zahm D, Hanusch C, Solbach C, Heinrich G, Hartkopf A, Schneeweiss A, Fasching P, Filmann N, Nekljudova V, Holtschmidt J, Stickeler E, Loibl S. Long-term outcomes of a randomized, open-label, phase II study comparing cabazitaxel versus paclitaxel as neoadjuvant treatment in patients with triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE). ESMO Open 2024; 9:103009.
24.04.2024Long-term outcomes of a randomized, open-label, phase II study comparing cabazitaxel versus paclitaxel as neoadjuvant treatment in patients with triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE).
24.04.2024ESMO Open 2024; 9:103009
Meyer-Wilmes P, Huober Jens, Untch Michael, Blohmer J-U, Janni Wolfgang, Denkert Carsten, Klare Peter, Link Theresa, Rhiem Kerstin, Bayer C, Reinisch Mattea, Bjelic-Radisic Vesna, Zahm Dirk Michael, Hanusch Claus, Solbach Christine, Heinrich Georg, Hartkopf Andreas D, Schneeweiss Andreas, Fasching Peter Andreas, Filmann N, Nekljudova Valentina, Holtschmidt J, Stickeler Elmar, Loibl Sibylle
Baseline CD4 and expansion of γδ T cells correlate with response to durvalumab in triple-negative breast cancer patients.
Massa C, Karn T, Weber K, Schneeweiss A, Hanusch C, Blohmer J, Zahm D, Jackisch C, van Mackelenbergh M, Thomalla J, Marme F, Huober J, Müller V, Schem C, Mueller A, Stickeler E, Biehl K, Fasching P, Untch M, Loibl S, Denkert C, Seliger B. Baseline CD4 and expansion of γδ T cells correlate with response to durvalumab in triple-negative breast cancer patients. Clin Transl Med 2024; 14:e1617.
01.04.2024Baseline CD4 and expansion of γδ T cells correlate with response to durvalumab in triple-negative breast cancer patients.
01.04.2024Clin Transl Med 2024; 14:e1617
Massa Chiara, Karn Thomas, Weber Karsten E, Schneeweiss Andreas, Hanusch Claus, Blohmer Jens-Uwe, Zahm Dirk-Michael, Jackisch Christian, van Mackelenbergh Marion T, Thomalla Jörg, Marme Frederik, Huober Jens, Müller Volkmar, Schem Christian, Mueller Anja, Stickeler Elmar, Biehl Katharina, Fasching Peter Andreas, Untch Michael, Loibl Sibylle, Denkert Carsten, Seliger Barbara
Radiotherapy statements of the 18th St. Gallen International Breast Cancer Consensus Conference-a German expert perspective.
Krug D, Banys-Paluchowski M, Brucker S, Denkert C, Ditsch N, Fasching P, Haidinger R, Harbeck N, Heil J, Huober J, Jackisch C, Janni W, Kolberg H, Loibl S, Luftner D, van Mackelenbergh M, Radosa J, Reimer T, Welslau M, Wuerstlein R, Untch M, Budach W. Radiotherapy statements of the 18th St. Gallen International Breast Cancer Consensus Conference-a German expert perspective. Strahlenther Onkol 2024
23.02.2024Radiotherapy statements of the 18th St. Gallen International Breast Cancer Consensus Conference-a German expert perspective.
23.02.2024Strahlenther Onkol 2024
Krug David, Banys-Paluchowski Maggie, Brucker Sara Y, Denkert Carsten, Ditsch Nina, Fasching Peter Andreas, Haidinger Renate, Harbeck Nadia, Heil Jörg, Huober Jens, Jackisch Christian, Janni Wolfgang, Kolberg Hans-Christian, Loibl Sibylle, Luftner Diana, van Mackelenbergh Marion T, Radosa Julia C, Reimer Toralf, Welslau Manfred, Wuerstlein Rachel, Untch Michael, Budach Wilfried
RANK expression as an independent predictor for response to neoadjuvant chemotherapy in luminal-like breast cancer - a translational insight from the GeparX trial.
Link T, Blohmer J, Schmitt W, Kuhlmann J, Just M, Untch M, Stötzer O, Fasching P, Thill M, Reinisch M, Schneeweiss A, Wimberger P, Seiler S, Huober J, Jackisch C, Rhiem K, Hanusch C, Sinn B, Nekljudova V, Loibl S, Denkert C. RANK expression as an independent predictor for response to neoadjuvant chemotherapy in luminal-like breast cancer - a translational insight from the GeparX trial. Clin Cancer Res 2023
19.09.2023RANK expression as an independent predictor for response to neoadjuvant chemotherapy in luminal-like breast cancer - a translational insight from the GeparX trial.
19.09.2023Clin Cancer Res 2023
Link Theresa, Blohmer Jens-Uwe, Schmitt Wolfgang Daniel, Kuhlmann Jan Dominik, Just Marianne, Untch Michael, Stötzer Oliver, Fasching Peter Andreas, Thill Marc, Reinisch Mattea, Schneeweiss Andreas, Wimberger Pauline, Seiler Sabine, Huober Jens, Jackisch Christian, Rhiem Kerstin, Hanusch Claus, Sinn Bruno Valentin, Nekljudova Valentina, Loibl Sibylle, Denkert Carsten
Treatment of Early Breast Cancer: The 18th St. Gallen International Breast Cancer Consensus Conference against the Background of Current German Treatment Recommendations.
Untch M, Banys-Paluchowski M, Brucker S, Budach W, Denkert C, Ditsch N, Fasching P, Haidinger R, Heil J, Jackisch C, Janni W, Kolberg H, Krug D, Loibl S, Luftner D, van Mackelenbergh M, Radosa J, Reimer T, Welslau M, Wuerstlein R, Harbeck N, Huober J. Treatment of Early Breast Cancer: The 18th St. Gallen International Breast Cancer Consensus Conference against the Background of Current German Treatment Recommendations. Geburtshilfe Frauenheilkd 2023; 83:1102-1116.
12.09.2023Treatment of Early Breast Cancer: The 18th St. Gallen International Breast Cancer Consensus Conference against the Background of Current German Treatment Recommendations.
12.09.2023Geburtshilfe Frauenheilkd 2023; 83:1102-1116
Untch Michael, Banys-Paluchowski Maggie, Brucker Sara Y, Budach Wilfried, Denkert Carsten, Ditsch Nina, Fasching Peter Andreas, Haidinger Renate, Heil Jörg, Jackisch Christian, Janni Wolfgang, Kolberg Hans-Christian, Krug David, Loibl Sibylle, Luftner Diana, van Mackelenbergh Marion T, Radosa Julia C, Reimer Toralf, Welslau Manfred, Wuerstlein Rachel, Harbeck Nadia, Huober Jens
Identifying breast cancer patients at risk of relapse despite pathological complete response after neoadjuvant therapy.
Huober J, van Mackelenbergh M, Schneeweiss A, Seither F, Blohmer J, Denkert C, Tesch H, Hanusch C, Salat C, Rhiem K, Solbach C, Fasching P, Jackisch C, Reinisch M, Lederer B, Mehta K, Link T, Nekljudova V, Loibl S, Untch M. Identifying breast cancer patients at risk of relapse despite pathological complete response after neoadjuvant therapy. NPJ Breast Cancer 2023; 9:23.
07.04.2023Identifying breast cancer patients at risk of relapse despite pathological complete response after neoadjuvant therapy.
07.04.2023NPJ Breast Cancer 2023; 9:23
Huober Jens, van Mackelenbergh Marion T, Schneeweiss Andreas, Seither Fenja, Blohmer Jens-Uwe, Denkert Carsten, Tesch Hans, Hanusch Claus, Salat Christoph, Rhiem Kerstin, Solbach Christine, Fasching Peter Andreas, Jackisch Christian, Reinisch Mattea, Lederer Bianca, Mehta Keyur M, Link Theresa, Nekljudova Valentina, Loibl Sibylle, Untch Michael
Practice-Changing Perspectives regarding Systemic Therapy in Early Breast Cancer: Opinions of German Experts regarding the 17th St. Gallen International Consensus Conference
Kolberg-Liedtke C, Untch M, Thomssen C, Schneeweiss A, Müller V, Loibl S, Kühn T, Krug D, Janni W, Jackisch C, Huober J, Harbeck N, Haidinger R, Fasching P, Denkert C, Budach W, Brucker S, Luftner D, Thill M. Practice-Changing Perspectives regarding Systemic Therapy in Early Breast Cancer: Opinions of German Experts regarding the 17th St. Gallen International Consensus Conference. Breast Care (Basel) 2022; 17:336-345.
08.04.2022Practice-Changing Perspectives regarding Systemic Therapy in Early Breast Cancer: Opinions of German Experts regarding the 17th St. Gallen International Consensus Conference
08.04.2022Breast Care (Basel) 2022; 17:336-345
Kolberg-Liedtke Cornelia, Untch Michael, Thomssen Christoph, Schneeweiss Andreas, Müller Volkmar, Loibl Sibylle, Kühn Thorsten, Krug David, Janni Wolfgang, Jackisch Christian, Huober Jens, Harbeck Nadia, Haidinger Renate, Fasching Peter A, Denkert Carsten, Budach Wilfried, Brucker Sara Y, Luftner Diana, Thill Marc
Pathological Response in the Breast and Axillary Lymph Nodes after Neoadjuvant Systemic Treatment in Patients with Initially Node-Positive Breast Cancer Correlates with Disease Free Survival: An Exploratory Analysis of the GeparOcto Trial
Gerber B, Untch M, Kast K, Jackisch C, Thomalla J, Seither F, Blohmer J, Rhiem K, Fasching P, Nekljudova V, Loibl S, Hahn M, Klare P, Ataseven B, Schneeweiss A, Möbus V, Golatta M, Tesch H, Krug D, Hanusch C, Denkert C, Lübbe K, Heil J, Huober J, Kühn T. Pathological Response in the Breast and Axillary Lymph Nodes after Neoadjuvant Systemic Treatment in Patients with Initially Node-Positive Breast Cancer Correlates with Disease Free Survival: An Exploratory Analysis of the GeparOcto Trial. Cancers (Basel) 2022; 14
20.01.2022Pathological Response in the Breast and Axillary Lymph Nodes after Neoadjuvant Systemic Treatment in Patients with Initially Node-Positive Breast Cancer Correlates with Disease Free Survival: An Exploratory Analysis of the GeparOcto Trial
20.01.2022Cancers (Basel) 2022; 14
Gerber Bernd, Untch Michael, Kast Karin, Jackisch Christian, Thomalla Jörg, Seither Fenja, Blohmer Jens-Uwe, Rhiem Kerstin, Fasching Peter A, Nekljudova Valentina, Loibl Sibylle, Hahn Markus, Klare Peter, Ataseven Beyhan, Schneeweiss Andreas, Möbus Volker, Golatta Michael, Tesch Hans, Krug David, Hanusch Claus, Denkert Carsten, Lübbe Kristina, Heil Jörg, Huober Jens, Kühn Thorsten
Effect of Denosumab Added to 2 Different nab-Paclitaxel Regimens as Neoadjuvant Therapy in Patients With Primary Breast Cancer: The GeparX 2 × 2 Randomized Clinical Trial
Blohmer J, Jackisch C, Rhiem K, Solbach C, Hanusch C, Seither F, Denkert C, Engels K, Nekljudova V, Loibl S, Thill M, Huober J, Link T, Reinisch M, Just M, Untch M, Stötzer O, Fasching P, Schneeweiss A, Wimberger P, Seiler S, GBG and AGO-B. Effect of Denosumab Added to 2 Different nab-Paclitaxel Regimens as Neoadjuvant Therapy in Patients With Primary Breast Cancer: The GeparX 2 × 2 Randomized Clinical Trial. JAMA Oncol 2022; 8:1010-1018.
01.01.2022Effect of Denosumab Added to 2 Different nab-Paclitaxel Regimens as Neoadjuvant Therapy in Patients With Primary Breast Cancer: The GeparX 2 × 2 Randomized Clinical Trial
01.01.2022JAMA Oncol 2022; 8:1010-1018
Blohmer Jens-Uwe, Jackisch Christian, Rhiem Kerstin, Solbach Christine, Hanusch Claus, Seither Fenja, Denkert Carsten, Engels Knut, Nekljudova Valentina, Loibl Sibylle, Thill Marc, Huober Jens, Link Theresa, Reinisch Mattea, Just Marianne, Untch Michael, Stötzer Oliver, Fasching Peter A, Schneeweiss Andreas, Wimberger Pauline, Seiler Sabine, GBG and AGO-B
Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer
Schneeweiss A, Blohmer J, Fasching P, Solbach C, Schmutzler R, Huober J, Rhiem K, Nekljudova V, Lübbe K, Loibl S, Jackisch C, Untch M, Link T, Michel L, Möbus V, Tesch H, Klare P, Hahnen E, Denkert C, Kast K, Pohl-Rescigno E, Hanusch C, GBG and AGO-B. Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer. Eur J Cancer 2021
17.11.2021Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer
17.11.2021Eur J Cancer 2021
Schneeweiss Andreas, Blohmer Jens-Uwe, Fasching Peter A, Solbach Christine, Schmutzler Rita K, Huober Jens, Rhiem Kerstin, Nekljudova Valentina, Lübbe Kristina, Loibl Sibylle, Jackisch Christian, Untch Michael, Link Theresa, Michel Laura L, Möbus Volker, Tesch Hans, Klare Peter, Hahnen Eric, Denkert Carsten, Kast Karin, Pohl-Rescigno Esther, Hanusch Claus, GBG and AGO-B
Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness
Metzger-Filho O, von Minckwitz G, Rastogi P, Li L, Cheng L, Maag D, Wolmark N, Denkert C, Symmans W, Geyer C, Loibl S, Sikov W, Golshan M, Collier K, Asad S, Ansell P, Watson M, Bae J, Cherian M, O'Shaughnessy J, Untch M, Rugo H, Huober J, Stover D. Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness. NPJ Breast Cancer 2021; 7:142.
11.11.2021Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness
11.11.2021NPJ Breast Cancer 2021; 7:142
Metzger-Filho Otto, von Minckwitz Gunter, Rastogi Priya, Li Lang, Cheng Lijun, Maag David, Wolmark Norman, Denkert Carsten, Symmans W Fraser, Geyer Charles E, Loibl Sibylle, Sikov William M, Golshan Mehra, Collier Katharine, Asad Sarah, Ansell Peter J, Watson Mark, Bae Junu, Cherian Mathew, O'Shaughnessy Joyce, Untch Michael, Rugo Hope S, Huober Jens, Stover Daniel G
Phase III randomised trial comparing intense dose-dense chemotherapy to tailored dose-dense chemotherapy in high-risk early breast cancer (GAIN-2)
Möbus V, Reinisch M, Link T, Sinn B, Janni W, Denkert C, Furlanetto J, Engels K, Solbach C, Schmatloch S, Rey J, Burchardi N, Loibl S, Stickeler E, Huober J, Lück H, Ladda E, Klare P, Schmidt M, Schneeweiss A, Grischke E, Wachsmann G, Forstbauer H, Untch M, Marme F, Blohmer J, Jackisch C, GBG and AGO-B. Phase III randomised trial comparing intense dose-dense chemotherapy to tailored dose-dense chemotherapy in high-risk early breast cancer (GAIN-2). Eur J Cancer 2021; 156:138-148.
24.08.2021Phase III randomised trial comparing intense dose-dense chemotherapy to tailored dose-dense chemotherapy in high-risk early breast cancer (GAIN-2)
24.08.2021Eur J Cancer 2021; 156:138-148
Möbus Volker, Reinisch Mattea, Link Theresa, Sinn Bruno V, Janni Wolfgang, Denkert Carsten, Furlanetto Jenny, Engels Knut, Solbach Christine, Schmatloch Sabine, Rey Julia, Burchardi Nicole, Loibl Sibylle, Stickeler Elmar, Huober Jens, Lück Hans-Joachim, Ladda Ekkehart, Klare Peter, Schmidt Marcus, Schneeweiss Andreas, Grischke Eva-Maria, Wachsmann Grischa, Forstbauer Helmut, Untch Michael, Marme Frederik, Blohmer Jens-Uwe, Jackisch Christian, GBG and AGO-B
Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials
Denkert C, Huober J, Rhiem K, Marme F, Reimer T, Schmidt M, Sinn B, Janni W, Stickeler E, Michel L, Stötzer O, Hahnen E, Furlanetto J, Seiler S, Nekljudova V, Untch M, Solbach C, Lübbe K, Seither F, Schneeweiss A, Link T, Blohmer J, Just M, Wimberger P, Forberger A, Tesch H, Jackisch C, Schmatloch S, Reinisch M, Solomayer E, Schmitt W, Hanusch C, Fasching P, Loibl S. Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials. Lancet Oncol 2021; 22:1151-1161.
09.07.2021Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials
09.07.2021Lancet Oncol 2021; 22:1151-1161
Denkert Carsten, Huober Jens, Rhiem Kerstin, Marme Frederik, Reimer Toralf, Schmidt Marcus, Sinn Bruno V, Janni Wolfgang, Stickeler Elmar, Michel Laura, Stötzer Oliver, Hahnen Eric, Furlanetto Jenny, Seiler Sabine, Nekljudova Valentina, Untch Michael, Solbach Christine, Lübbe Kristina, Seither Fenja, Schneeweiss Andreas, Link Theresa, Blohmer Jens-Uwe, Just Marianne, Wimberger Pauline, Forberger Almuth, Tesch Hans, Jackisch Christian, Schmatloch Sabine, Reinisch Mattea, Solomayer Erich F, Schmitt Wolfgang D, Hanusch Claus, Fasching Peter A, Loibl Sibylle
Utility of the CPS + EG scoring system in triple-negative breast cancer treated with neoadjuvant chemotherapy
Marme F, Loibl S, Lederer B, Tesch H, Hanusch C, Denkert C, Rey J, Rhiem K, Link T, Nekljudova V, Jackisch C, Fasching P, Huober J, Blohmer J, Schneeweiss A, Michel L, Solbach C, Untch M. Utility of the CPS + EG scoring system in triple-negative breast cancer treated with neoadjuvant chemotherapy. Eur J Cancer 2021; 153:203-212.
26.06.2021Utility of the CPS + EG scoring system in triple-negative breast cancer treated with neoadjuvant chemotherapy
26.06.2021Eur J Cancer 2021; 153:203-212
Marme Frederik, Loibl Sibylle, Lederer Bianca, Tesch Hans, Hanusch Claus, Denkert Carsten, Rey Julia, Rhiem Kerstin, Link Theresa, Nekljudova Valentina, Jackisch Christian, Fasching Peter A, Huober Jens, Blohmer Jens-Uwe, Schneeweiss Andreas, Michel Laura, Solbach Christine, Untch Michael
Treatment of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: German Expert Opinions on the 17th International St. Gallen Consensus Conference
Untch M, Harbeck N, Thill M, Schneeweiss A, Müller V, Luftner D, Loibl S, Kühn T, Krug D, Kolberg-Liedtke C, Janni W, Jackisch C, Huober J, Haidinger R, Denkert C, Budach W, Brucker S, Fasching P, Thomssen C. Treatment of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: German Expert Opinions on the 17th International St. Gallen Consensus Conference. Geburtshilfe Frauenheilkd 2021; 81:637-653.
19.05.2021Treatment of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: German Expert Opinions on the 17th International St. Gallen Consensus Conference
19.05.2021Geburtshilfe Frauenheilkd 2021; 81:637-653
Untch Michael, Harbeck Nadia, Thill Marc, Schneeweiss Andreas, Müller Volkmar, Luftner Diana, Loibl Sibylle, Kühn Thorsten, Krug David, Kolberg-Liedtke Cornelia, Janni Wolfgang, Jackisch Christian, Huober Jens, Haidinger Renate, Denkert Carsten, Budach Wilfried, Brucker Sara Y, Fasching Peter A, Thomssen Christoph
Association of Immunophenotype With Pathologic Complete Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Secondary Analysis of the BrighTNess Phase 3 Randomized Clinical Trial
Filho O, Rugo H, Huober J, Golshan M, Sikov W, von Minckwitz G, Rastogi P, Maag D, Wolmark N, Denkert C, Untch M, O'Shaughnessy J, Stover D, Asad S, Ansell P, Watson M, Loibl S, Geyer C, Bae J, Collier K, Cherian M, Symmans W. Association of Immunophenotype With Pathologic Complete Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Secondary Analysis of the BrighTNess Phase 3 Randomized Clinical Trial. JAMA Oncol 2021; 7:603-608.
01.04.2021Association of Immunophenotype With Pathologic Complete Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Secondary Analysis of the BrighTNess Phase 3 Randomized Clinical Trial
01.04.2021JAMA Oncol 2021; 7:603-608
Filho Otto Metzger, Rugo Hope S, Huober Jens, Golshan Mehra, Sikov William M, von Minckwitz Gunter, Rastogi Priya, Maag David, Wolmark Norman, Denkert Carsten, Untch Michael, O'Shaughnessy Joyce, Stover Daniel G, Asad Sarah, Ansell Peter J, Watson Mark, Loibl Sibylle, Geyer Charles E, Bae Junu, Collier Katharine, Cherian Mathew, Symmans W Fraser
Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors - An analysis of 2765 patients from neoadjuvant clinical trials
Villegas S, Huober J, Lederer B, van Mackelenbergh M, Tesch H, Jackisch C, Rezai M, Sinn P, Sinn B, Hackmann J, Kiechle M, Schneeweiss A, Weichert W, Denkert C, Schmitt W, Hanusch C, Nekljudova V, Pfarr N, Engel J, Untch M, Schrodi S, Holms F, Ulmer H, Fasching P, Weber K, Albig C, Heinrichs C, Marme F, Hartmann A, Loibl S. Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors - An analysis of 2765 patients from neoadjuvant clinical trials. Eur J Cancer 2021; 148:159-170.
18.03.2021Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors - An analysis of 2765 patients from neoadjuvant clinical trials
18.03.2021Eur J Cancer 2021; 148:159-170
Villegas Sonia L, Huober Jens, Lederer Bianca, van Mackelenbergh Marion, Tesch Hans, Jackisch Christian, Rezai Mahdi, Sinn Peter, Sinn Bruno V, Hackmann John, Kiechle Marion, Schneeweiss Andreas, Weichert Wilko, Denkert Carsten, Schmitt Wolfgang D, Hanusch Claus, Nekljudova Valentina, Pfarr Nicole, Engel Jutta, Untch Michael, Schrodi Simone, Holms Frank, Ulmer Hans U, Fasching Peter A, Weber Karsten E, Albig Christian, Heinrichs Clemens, Marme Frederik, Hartmann Arndt, Loibl Sibylle